SynthesisReproductive health2026
Global prevalence of multimorbidity during pregnancy: a systematic review and meta-analysis.
Synthesis in Reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultimorbidity, defined as having two or more coexisting physical or mental health conditions, increases the risk of complications and need of specialist care during pregnancy. In women of reproductive age, pregnancy represents a critical period during which multimorbidity may manifest or be exacerbated. Multimorbidity during pregnancy has been associated with a wide range of adverse maternal and neonatal outcomes. This systematic review aims to estimate the global and regional prevalences of multimorbidity during pregnancy, as well as to understand how multimorbidity is defined across studies.
methodsWe systematically searched four databases (Medline, Embase, CINAHL and Web of Science) for observational studies published from January 1, 2015, to September 26, 2025, without language or geographic restrictions. The protocol was registered in the PROSPERO database (CRD420251153876). We included peer-reviewed cross-sectional and cohort studies including ≥ 200 pregnant women, reporting the prevalence of multimorbidity. Data screening, extraction and quality assessment were conducted independently by two reviewers following PRISMA 2020 and Joanna Briggs Institute guidelines. Pooled prevalence was estimated via random-effects meta-analysis, and explored through predefined subgroup analyses.
resultsThe literature search retrieved 6,243 studies, and after title/abstract and full-text screening, 18 observational studies across eight countries were included in the review. The pooled prevalence of multimorbidity during pregnancy was 7.18% (95% CI: 3.31-14.89, I2 = 100.0%), with regional differences: 1.74% (95% CI: 0.46-6.37, I2 = 99.98%) in Asia, 9.07% (95% CI: 3.01-24.30, I2 = 100.0%) in North America, 11.17% (95% CI: 1.22-56.18, I2 = 99.94%) in Oceania and 12.64% (95% CI: 3.41-37.24, I2 = 99.99%) in Europe. However, the wide confidence intervals for Europe and Oceania warrant cautious interpretation of regional comparisons.
conclusionMultimorbidity during pregnancy is a significant and under-researched global health concern. The pooled prevalence of 7.18% reflects a synthesis of highly heterogeneous studies and should not be interpreted as a definitive estimate of the global burden. More standardized research, particularly in low- and middle-income countries, is needed to generate more representative prevalence estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.